Know Cancer

forgot password

An Open-label, Multicenter Phase II Study to Compare the Efficacy and Safety of RAD001 as First-line Followed by Second-line Sunitinib Versus Sunitinib as First-line Followed by Second-line RAD001 in the Treatment of Patients With Metastatic Renal Cell Carcinoma.

Phase 2
18 Years
Open (Enrolling)
Renal Cell Carcinoma

Thank you

Trial Information

An Open-label, Multicenter Phase II Study to Compare the Efficacy and Safety of RAD001 as First-line Followed by Second-line Sunitinib Versus Sunitinib as First-line Followed by Second-line RAD001 in the Treatment of Patients With Metastatic Renal Cell Carcinoma.

Inclusion Criteria:

1. Patients with advanced renal cell carcinoma.

2. Patients with at least one measurable lesion.

3. Patients with a Karnofsky Performance Status ≥70%.

4. Adequate bone marrow function.

5. Adequate liver function.

6. Adequate renal function.

7. Left ventricular ejection fraction (LVEF) ≥ lower limit of institutional normal (LLN)

8. Women of childbearing potential must have had a negative serum pregnancy test within
14 days prior to the administration of the study medication. Adequate contraception
must be used while on study.

Exclusion Criteria:

1. Less than 4 weeks post-major surgery

2. Patients who had radiation therapy within 4 weeks prior to start of study treatment
(palliative radiotherapy to bone lesions allowed within 2 weeks prior to study
treatment start).

3. Patients in need for major surgical procedure during the course of the study

4. Patients with a serious non-healing wound, ulcer, or bone fracture

5. Patients with a history of seizure(s) not controlled with standard medical therapy

6. Patients who have received prior systemic treatment for their metastatic RCC

7. Patients who have previously received systemic mTOR inhibitors (sirolimus,
temsirolimus, everolimus) or VEGF inhibitors. Note: History of adjuvant
immunotherapy, vaccines or adjuvant sorafenib following localized surgical
nephrectomy is acceptable.

8. Patients with a known hypersensitivity to RAD001 (everolimus) or other rapamycins
(sirolimus, temsirolimus) or to its excipients Patients with a known hypersensitivity
to RAD001 (everolimus) or other rapamycins or to its excipients

9. Patients with a known hypersensitivity to sunitinib or its excipients

10. Untreated central nervous system (CNS) metastases. Note: Subjects who have
previously-treated CNS metastases (surgery plus or minus radiotherapy, radiosurgery,
or gamma knife) and meet all 3 of the following criteria are eligible:

- Are asymptomatic and,

- have had no evidence of active CNS metastases for ≥ 6 months prior to enrollment

- have no requirement for steroids or enzyme-inducing anticonvulsants (EIAC)

11. Clinically significant gastrointestinal abnormalities including, but not limited to:

- Malabsorption syndrome

- Major resection of the stomach or small bowel that could affect the absorption
of study drug

- Active peptic ulcer disease

- Inflammatory bowel disease

- Ulcerative colitis, or other gastrointestinal conditions with increased risk of

- History of abdominal fistula, gastrointestinal perforation, or intra abdominal
abscess within 28 days prior to beginning study treatment.

12. Poorly controlled hypertension [defined as systolic blood pressure (SBP) of ≥150mmHg
or diastolic blood pressure (DBP) of ≥ 90mmHg]

13. Patients receiving chronic systemic treatment with corticosteroids or another
immunosuppressive agent

14. Patients with a known history of HIV seropositivity.

15. Patients with active bleeding.

16. Patients who have any severe and/or uncontrolled medical conditions or other
conditions within the past 12 months that could affect their participation in the
study such as:

- Cardiac angioplasty or stenting, unstable angina pectoris, symptomatic
peripheral vascular disease, symptomatic congestive heart failure (NYHA II, III,
IV), myocardial infarction ≤ 6 months prior to first study treatment, serious
uncontrolled cardiac arrhythmia, cerebrovascular accidents ≤ 6 months before
study treatment start.

- Prolongation of corrected QT interval (QTc) > 500 milliseconds (msecs).

- Severally impaired lung function as defined as spirometry and DLCO that is 50%
of the normal predicted value and/or 02 saturation that is 88% or less at rest
on room air.

- Poorly controlled diabetes as defined by fasting serum glucose >2.0 x ULN.

- Any active (acute or chronic) or uncontrolled infection/disorders that impair
the ability to evaluate the patient or for the patient to complete the study.

- Liver disease such as chronic active hepatitis or chronic persistent hepatitis.

17. History of cerebrovascular accident (CVA) including transient ischemic attack (TIA).

18. History of pulmonary embolism or untreated deep venous thrombosis (DVT) within the
past 6 months. Note: Subjects with recent DVT who have been treated with therapeutic
anti-coagulating agents for at least 6 weeks are eligible.

19. Patients who have a history of another primary malignancy and off treatment for ≤ 3

20. Female patients of child-bearing potential who are not using adequate birth control
methods, or who are pregnant or breast feeding.

21. Patients who are using other investigational agents or who had received
investigational drugs ≤ 2 weeks prior to study treatment start.

22. Patients unwilling or unable to comply with the protocol.

Other protocol-defined inclusion/exclusion criteria may apply

Type of Study:


Study Design:

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To assess if Progression Free Survival (PFS) after first-line of treatment in patients who receive RAD001 will be non-inferior to the PFS of patients who receive sunitinib after first-line treatment.

Outcome Time Frame:

6 - 12 months

Safety Issue:


Principal Investigator

Novartis Pharmaceuticals

Investigator Role:

Study Director

Investigator Affiliation:

Novartis Pharmaceuticals


United States: Food and Drug Administration

Study ID:




Start Date:

October 2009

Completion Date:

June 2014

Related Keywords:

  • Renal Cell Carcinoma
  • RAD001
  • everolimus
  • Afinitor®
  • Sutent®
  • sunitinib
  • renal cell carcinoma
  • kidney cancer
  • metastatic renal cell cancer
  • advanced kidney cancer
  • Carcinoma
  • Carcinoma, Renal Cell



Cooper Cancer Center Voorhees, New Jersey  08043
East Texas Medical Center Cancer Institute Tyler, Texas  75701
Summit Cancer Care Savannah, Georgia  31405
Arena Oncology Associates, PC Great Neck, New York  11021
Lynn Cancer Institute Boca Raton, Florida  33428
Georgia Health Sciences University Dept. of MCG Augusta, Georgia  30912
Levine Cancer Institute Oncology Charlotte, North Carolina  28203
University of South Alabama / Mitchell Cancer Institute Dept. of Mitchell Cancer Inst. Mobile, Alabama  36688
Weinberg Cancer Institute at Franklin Square Hospital Baltimore, Maryland  21237-3998
Northeast Georgia Cancer Care Dept of NE Georgia Cancer (2) Athens, Georgia  30607
The West Clinic Dept. of the West Clinic Memphis, Tennessee  38120
Highlands Oncology Group HighlandsOncGrp-Bentonville(2) Fayetteville, Arkansas  72703
University of California San Diego Dept of Moores Cancer Ctr (5) La Jolla, California  92093-0658
University of Colorado Dept. of Anschutz Cancer (2) Aurora, Colorado  80045
Memorial Sloan Kettering Cancer Center Dept. of MSKCC New York, New York  10021
SUNY - Upstate Medical University Div. of Hematology-Oncology Syracuse, New York  13210
Utah Cancer Specialists Dept.of Utah Cancer Spec. (3) Salt Lake City, Utah  84103
Hematology and Oncology Specialists SC Metairie, Louisiana  70006
The Center for Cancer and Blood Disorders Dept. of The Ctr for C & BD(2) Fort Worth, Texas  76104
University of Alabama at Birmingham/ Kirklin Clinic Comprehensive CancerCenter (1) Birmingham, Alabama  35294-0006
University of California at Los Angeles Dept. of UCLA (3) Los Angeles, California  90095
Norwalk Hospital Norwlak SC Norwalk, Connecticut  06856
Georgetown University/Lombardi Cancer Center Dept.of Lombardi Cancer Ctr (2 Washington, District of Columbia  20007-2197
University of Miami SC Miami, Florida  33136
MD Anderson Cancer Center - Orlando Dept.ofMDACC-Orlando Orlando, Florida  32806
NorthwesternUniv.Med.School/Robert H. Lurie Comp.Cancer Ctr Dept.ofNorthwesternMemHospital Chicago, Illinois  60611
Loyola University Medical Center /Cardinal Bernardin Cancer Cardinal Bernardin Cancer (3) Maywood, Illinois  60153
VA Maryland Health Care Dept.of GreenbaumCancerCent(7) Baltimore, Maryland  21201
Billings Clinic Dept of Billings Clinic(2) Billings, Montana  59107
Hackensack University Medical Center DeptofHackensackUniv.MedCtr. Hackensack, New Jersey  07601
UNC/ Lineberger Comprehensive Cancer Center Dept. of LinbergerCancerCtr(3) Chapel Hill, North Carolina  27599-7295
Duke University Medical Center Duke Durham, North Carolina  27710
University of Oklahoma Health Sciences Center Dept of OHSC Oklahoma City, Oklahoma  73104
St. Luke's Hospital and Health Network St Luke's Hospital (2) Bethlehem, Pennsylvania  
Aurora Advanced Healthcare SC Milwaukee, Wisconsin  53215